SAR439483
Total Payments
$99,188
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $99,188 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $99,188 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2 Dose Escalation Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D | SANOFI US SERVICES INC. | $99,188 | 0 |
Top Doctors Receiving Payments for SAR439483
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $99,188 | 4 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $99,188
Product Information
- Type Drug
- Total Payments $99,188
- Total Doctors 0
- Transactions 4
About SAR439483
SAR439483 is a drug associated with $99,188 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2019 to 2019. In 2019, $99,188 was paid across 4 transactions to 0 doctors.
The most common payment nature for SAR439483 is "Unspecified" ($99,188, 100.0% of total).
SAR439483 is associated with 1 research study, including "A Phase 1/2 Dose Escalation Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D" ($99,188).